The Obesity Drug Revolution
GLP-1 receptor agonists like semaglutide and tirzepatide have transformed obesity treatment. Clinical trials show 15-25 percent body weight reduction, approaching the effectiveness of bariatric surgery without the surgical risk. Demand has exceeded supply. The drugs reduce cardiovascular risk factors and may have benefits for kidney disease and addiction. Long-term safety data is still being collected. The economic implications are enormous: reduced healthcare costs could offset the high drug prices within a decade.